Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Peptide-based influenza vaccine formulation

A preparation and vaccine technology, applied in the field of peptide-based influenza vaccine preparations, to achieve broad protection and improve humoral response

Inactive Publication Date: 2011-10-05
VARIATION BIOTECHNOLOGIES INC
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, a major concern with peptide-based subunit vaccines is the ability of linear peptides to induce antibodies that recognize conformational B- and T-cell epitopes

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Peptide-based influenza vaccine formulation
  • Peptide-based influenza vaccine formulation
  • Peptide-based influenza vaccine formulation

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0166] In this example, B6 mice were immunized with INF-01P vaccine plus Alum, Ribi or Montanide, or commercial vaccine (2004-2005 season). Sera from vaccinated mice were obtained one day before virus challenge. Mice were challenged with pathogenic A / HK / 1 / 68-MA20c virus, followed by three weeks of follow-up challenges.

[0167] The INF-01P vaccine is based on the 4 human influenza sequence discontinuity construct formulations as shown in Table 19.

[0168] Table 19: INF-01P Influenza Vaccine Formulations

[0169] INF-HA-1-V1 (SEQ ID NO: 1)

YACKRGGKSSGSSYPVLNVSY (SEQ ID NOS: 1-16)

---H------------S-TM

INF-HA-1-V2 (SEQ ID NO: 17)

KKGSVHHPSTITEQTSLYVNA (SEQ ID NOS: 17-32)

-S-------------T--QQ-

[0170] INF-HA-1-V3 (SEQ ID NO: 33)

DVLFSVESPNNKNKDPIDTCD (SEQ ID NOS: 33-48)

------K-V-----ES-----

INF-HA-1-V4 (SEQ ID NO: 49)

YVSVSTSRIASRPKVRGQSGR (SEQ ID NOS: 49-64)

--T--S---G---W--------

[0171] Figure 9 Hu...

Embodiment 2

[0175] B6 mice were immunized with INFE-01P (equine influenza) vaccine plus alum or commercial vaccine (2004-2005 season). Test mouse sera against several influenza strains (H3N2 A / Hong Kong / 1 / 68g, H1 N1 A / FM / 1 / 47, H5N1 A / Hong Kong / 213 / 2003, B / Mass / 3 / 66 and H1 N1 A / NewCaledonia / 20 / 1999) HAI activity. Sera were obtained after the first vaccination.

[0176] INFE-01P vaccine is based on 4 equine influenza sequence discontinuous site construct preparations as shown in Table 20:

[0177] Table 20: INFE-01P Equine Influenza Vaccine Formulations

[0178] INFE-HA-1-V1 (SEQ ID NO: 185)

[0179] Figure 12 Humoral immunity in mice immunized with INFE-01P, as measured by HAI titers, is demonstrated. As shown, humoral immunity against several strains of influenza virus was induced in mice immunized with this exemplary equine vaccine formulation compared to mice vaccinated with commercial vaccine or adjuvant alone (control).

Embodiment 3

[0181] Hemagglutination (HAI) assay

[0182] The immunogenicity of individual or combined discontinuous epitope constructs was evaluated in mice. Mice immunized together with the four discontinuous epitope constructs developed antibodies capable of inhibiting the hemagglutination reactivity of the virus. Influenza-based discontinuous epitope constructs were shown to successfully mimic the discontinuous epitope as antibodies were elicited that inhibit hemagglutination caused by influenza virus.

[0183] Induction of functionally relevant antibodies against HA was measured using a standard HAI assay. The HAI titer induced by a candidate vaccine formulation was tested using a variety of different influenza strains to determine the extent of immunity induced by the vaccine formulation.

[0184] Figure 13 Shown are the results of hemagglutination assays performed in the murine vaccine study. Each vaccine group received a different vaccine formulation or phosphate buffered sa...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

Peptide-based anti-influenza formulations against influenza A and B are disclosed. The peptides are derived from influenza-based epitopes. The formulations are based on peptide mixtures which may be formulated so that variability is present at particular residues. The formulations can be used to prepare vaccines for preventing influenza in human, avian, murine or equine animals.

Description

[0001] Cross References to Related Applications [0002] This application claims priority to US Provisional Patent Application No. 60 / 686,041, filed June 1, 2005, which is incorporated herein by reference. technical field [0003] The present invention relates generally to antiviral formulations, and more particularly to peptide-based influenza vaccine formulations. Background technique [0004] Influenza is a common respiratory infectious disease related to Orthomyxoviridae family of viruses. Due to the high variability of the virus, annual vaccination with a vaccine reformulated to account for strain variation is usually required. Despite reformulation, it is impossible for a vaccine to include all the different strains that infect people around the world in a given season. [0005] Although an effective vaccine against influenza is currently available, it must be reformulated annually due to antigenic variation in the surface proteins of the virus. One obstacle to refo...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K39/145A61K39/39A61P31/16
CPCC12N2760/16134C12N2760/16122A61K39/00A61K2039/55505C07K14/005A61K39/145A61K2039/55566C12N2760/16234A61K39/12A61P31/16A61K38/16A61K39/39
Inventor 若泽·V·托里斯
Owner VARIATION BIOTECHNOLOGIES INC
Features
  • Generate Ideas
  • Intellectual Property
  • Life Sciences
  • Materials
  • Tech Scout
Why Patsnap Eureka
  • Unparalleled Data Quality
  • Higher Quality Content
  • 60% Fewer Hallucinations
Social media
Patsnap Eureka Blog
Learn More

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2025 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com